论文部分内容阅读
目的:观察长秀霖加阿卡波糖治疗预混胰岛素类似物血糖控制不佳的2型糖尿病(T2DM)患者的有效性、安全性。方法:本院60例使用门冬胰岛素30注射液效果欠佳的T2DM患者改用睡前长秀霖加餐时阿卡波糖治疗。记录调整治疗前,治疗后1个月,3个月,6个月空腹血糖(FPG),餐后2小时血糖(2hPG),糖化血红蛋白(HbA1c),体重,体重指数(BMI),胰岛素剂量,低血糖事件等。结果:治疗6个月后,两组FBG,2hPG,HBA1C,胰岛素剂量较前均明显下降(P<0.05)。且长秀霖加阿卡波糖低血糖发生率低,并无夜间低血糖事件。结论:长秀霖加阿卡波糖治疗门冬胰岛素30控制血糖欠佳的2型糖尿病患者,血糖控制良好,低血糖发生率低。
Objective: To observe the effectiveness and safety of Chang-Xi-Lin plus acarbose in the treatment of type 2 diabetes mellitus (T2DM) with poor blood glucose control of premixed insulin analogs. Methods: 60 patients with asymptomatic insulin injections in 60 patients with poor outcomes in patients with T2DM to bedtime Changxiu Lin meal acarbose treatment. Record before treatment, 1 month after treatment, 3 months, 6 months fasting blood glucose (FPG), 2 hours postprandial blood glucose (2hPG), HbA1c, body weight, body mass index (BMI), insulin dose, Hypoglycemia events. Results: After 6 months of treatment, the doses of FBG, 2hPG, HBA1C and insulin in the two groups decreased significantly (P <0.05). And Changxiu Lin plus acarbose low incidence of hypoglycemia, no nighttime hypoglycemic events. Conclusion: Changxiu lin plus acarbose treatment of aspartic insulin 30 control type 2 diabetes patients with poor blood glucose, good glycemic control, low incidence of hypoglycemia.